• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PFRM3.SA
Share

Profarma Distribuidora de Produtos Farmacêuticos S.A. Stocks

R$ 7.18Last Updated 14.08.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

R$ 170.08M

R$ 7.18
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1961 and headquartered in Rio de Janeiro, Brazil, Profarma Distribuidora de Produtos Farmacêuticos S.A. is a prominent player in the Brazilian healthcare market, focusing on both the wholesale and retail sales of pharmaceutical and hospital supplies. The company's operations are divided into distinct Distribution and Retail segments. Its comprehensive product offerings include a vast array of pharmaceuticals, such as brand-name drugs, generic alternatives, and over-the-counter medications. Profarma also supplies essential hospital products, including injectable and infusion therapies for specialized medical areas like oncology, endocrinology, rheumatology, infectology, and hematology. Furthermore, it provides specific treatments such as vaccines for conditions like influenza, HPV, meningitis, hepatitis, chickenpox, and dengue, alongside specialized medicines for rare and complex diseases. Beyond pharmaceuticals, the company distributes a wide selection of personal care, beauty, and cosmetic items. This category encompasses shampoos, conditioners, treatment creams, hair dyes, baby products like diapers, soaps, deodorants, oral care essentials, sunscreens, men's grooming products, cosmetics, makeup, and skincare. Profarma also features proprietary lines under the Nº21, GOnutri, and Bem Básico brands, offering exclusive hygiene and beauty products, vitamins, and workshop items. Complementing these, convenience goods such as food products, blood pressure monitors, and scales are also available. The company extends its services to include promotional and logistical support, implementation of marketing campaigns, product recall management, development of bespoke solutions for laboratories, and oversight of clinical procedures. As of December 31, 2019, Profarma's infrastructure boasted eleven strategically located distribution centers across several Brazilian states (Alagoas, Bahia, Espírito Santo, Goiás, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio Grande do Sul, Rio de Janeiro, and São Paulo). Its retail footprint comprised approximately 196 stores operating under the Drogarias Tamoio, Drogasmil, Farmalife, and Rede Rosário banners, situated in the states of Rio de Janeiro, Goiás, Tocantins, Mato Grosso, and Distrito Federal.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.08.2026 21:00

Anthropic Is Aiming for a Record; Whoop Is Expanding Its Workforce: Key Takeaways on the IPO by August 16

16.08.2026 15:01

A Problem Worth Billions: How Much Is the EU Stock Market Losing Due to Mental Health Disorders?

15.08.2026 16:01

Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt

15.08.2026 13:01

A New Leader from China, Billionaires in Soccer, and Ray Dalio's Party

15.08.2026 03:06

Alphabet, Delta, and Construction: Where Buffett's Successor Invested

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026